ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb00017.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

摘要:

SUMMARYA review of the pharmacodynamic properties of aclarubicin compared with other anthracyclines: Metabolism, cellular uptake and distribution, intracellular binding, cell kinetics, cytotoxicity, resistance and influence on cell differentiation.

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb00018.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

摘要:

SUMMARYA survey of the adverse cardiovascular reactions elicited by treatment with the new anthracycline derivative aclarubicin is presented based on the results from selected animal experiments and available clinical data. With doxorubicin as a reference experimental studies have shown that cardiotoxicity from aclarubicin is more than ten‐fold lower, regarding both acute and chronic damage. It is premature to draw definite conclusions regarding the entire cardiotoxic profile in humans. ECG‐manifestations in the early treatment period with prolongation of the QTc‐interval may signal risk of severe ventricular arrhythmias in rare cases.The trend when reviewing the phase I‐II trials with aclarubicin in acute leukaemia seems to be low incidence of chronic cardiotoxicity in spite of prior daunorubicin therapy — even in considerable doses. Thus, published clinical data stimulate the pursuance of randomized phase III trials comparing aclarubicin to conventional anthracyclines to substantiate the supposed improved therapeutic index of this new d

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb00019.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

摘要:

SUMMARYAclarubicin (ACM) was administered as induction treatment to 38 evaluable patients with acute myeloid leukaemia (AML) who were either refractory to initial chemotherapy or in relapse. Thirteen patients received daily doses of ACM while the remaining 25 were given 10‐day courses with 10‐day intervals between courses. The overall CR rate was 34% and the incidence and severity of the toxic effects were related to the dose of ACM administered per course of therapy. Our results indicate that ACM is a major new drug for the treatment of

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb00020.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

摘要:

SUMMARYNineteen patients with acute myelogenous leukaemia refractory to regimens including daunorubicin (relapsed or resistant to the induction treatment) received aclarubicin as single‐agent chemotherapy in a dose of 40 mg/m2daily for 5–7 days. Among 17 evaluable patients one achieved complete remission, and two obtained partial remission. Side effects were acceptable. The chosen dose of aclarubicin appeared to be suboptimal. However, several arguments suggest that aclarubicin in combination with other cytotoxic agents should be evaluated as first‐line chemotherapy of acute myelogenous leuk

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb00021.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

摘要:

SUMMARYTwenty‐three elderly patients with untreated acute nonlymphocytic leukaemia (ANLL) ranging in age from 61 to 84 yr were randomly allocated to treatment with either aclarubicin, cytarabine and thioguanine (TAA) or daunorubicin, cytarabine and thioguanine (TAD). Complete remission was achieved in 6/13 and 4/10 patients, respectively. There was no difference in the number of courses to complete remission between the two therapy protocols. There were 7 deaths during induction treatment in the TAA group and 3 in the TAD group, probably due to chemotherapy induced granulocytopenia with septicaemia. The haematological toxicity was comparable in complete responders of the two treatment arms. These data indicate that aclarubicin is an effective drug in ANLL and that older patients respond to intensive chemotherapy in a similar manner as younger patients with this disease. However, treatment related deaths are common and the need for equipotent but less toxic regimens is paramount. This is especially true for patients with signs of heart, lung, kidney and liver diseas

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb00022.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

摘要:

SUMMARYThe results of this trial have been published elsewhere (1).

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb00023.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

摘要:

SUMMARYDetails of the protocol will be published elsewhere together with the results from the trial.

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb00024.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

摘要:

SUMMARYAclarubicin (ACM), 25 mg/m2daily for seven days, was administered as induction therapy to 40 patients with relapsing or refractory acute leukaemias. Eight complete (CR) and 1 partial (PR) remission were achieved in 29 evaluable AML patients (31%). A high CR rate was induced in patients treated at first relapse (6 out of 12 patients). A small proportion of AML resistant to daunorubicin or doxorubicin responded to ACM (3 out of 17 patients). Median remission duration was 5.5 months.In a pilot study ACM was combined with cytarabine for remission induction in 18 previously untreated patients or patients at first relapse with AML. Both drugs were administered on 7 consecutive days. CR was induced in 13 patients (72%). From these results it appears that the present scheduling of ACM in single agent and combined chemotherapy is effective in remission induction in previously untreated or relapsing AML.

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb00025.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

摘要:

SUMMARYTwenty‐five breast cancer patients previously not exposed to adriamycin, were treated with 30 mg/m2/day aclarubicin for four consecutive days. Out of the 19 evaluable cases 1 CR and 2 PR were observed giving an overall remission rate of 16%. No cardiotoxicity was observed. Myelotoxicity and hair loss were mild (WHO grades 1 and 2). Grade 2 and 3 nausea and vomiting occurred frequentl

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb00026.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY